Clinical Data ASCO26: AZ triplet makes waves in frontline liver cancer PharmaphorumEMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.OncologyRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) Pharmaphorum EMERALD-3 suggests a triplet regimen based on AstraZeneca’s Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: CordenPharma inks AmbioPharm buyout to continue peptide production expansionNext: Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn Related Stories Clinical Data Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs pharminent July 14, 2026 Clinical Data Major trial launched to explore GLP-1 benefit in dementia pharminent July 13, 2026 Clinical Data GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China pharminent July 10, 2026
